Emergent BioSolutions (EBS) said Monday its board has authorized the repurchase of up to $50 million of its common stock through March 27, 2026.
The new stock buyback program may be suspended or discontinued at any time, the vaccines and specialty medicines company said, adding it had around 54.3 million shares outstanding at the end of 2024.
Emergent shares were ahead 3% in Monday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.